In a meta-analysis of eight studies involving 323,439 people with overweight or obesity, tirzepatide did not significantly reduce major adverse cardiovascular events compared with GLP-1 receptor agonists. The estimates pointed toward fewer events, but the results were highly variable and most evidence came from observational studies, so causality cannot be inferred.
Meta-analysis — Systematic review and meta-analysis. Population: Adults with overweight or obesity. Sample size: 323 439 patients. Interventions: Tirzepatide.
Eight studies (one randomized and seven observational) including 323,439 patients were analysed. Tirzepatide was not associated with a statistically significant reduction in MACE compared with GLP-1 receptor agonists (HR 0.85, 95% CI 0.70-1.04; I² = 90.4%). All-cause mortality HR was 0.90 (95% CI 0.79-1.02) and cardiovascular mortality HR was 0.88 (95% CI 0.76-1.00). In an exploratory subgroup of patients with type 2 diabetes, all-cause mortality HR was 0.85 (95% CI 0.76-0.94) and heart failure HR was 0.75 (95% CI 0.58-0.97). Substantial heterogeneity was observed.
For researchers studying tirzepatide, this paper aggregates current evidence comparing its cardiovascular outcomes with GLP-1 receptor agonists in overweight and obesity, showing a trend toward fewer events that did not reach statistical significance for MACE. It does not establish a causal cardiovascular benefit over GLP-1 RAs, and the heterogeneity and observational design mean definitive conclusions await further randomized trials.
Peptide profiles: Tirzepatide.
All indexed evidence: Tirzepatide trials & papers.
Related studies: Peripheral nerve complications from medications utilised for weight loss: a systematic…, Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of…, Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory…, Comparative effects of drugs for adults with overweight or obesity: systematic review….